Dyspnea and activity limitation in COPD: mechanical factors.
Denis E O'Donnell, Pierantonio Laveneziana
https://pubmed.ncbi.nlm.nih.gov/17729066/Actively Recruiting
Led by Azienda Socio Sanitaria Territoriale di Lodi · Updated on 2026-06-24
23
Participants Needed
1
Research Sites
13 weeks
Total Duration
People with severe or very severe chronic obstructive pulmonary disease COPD often have pulmonary hyperinflation, where too much air is trapped in the lungs. This condition causes difficulty breathing and lowers quality of life. This study evaluates the immediate effect of a single session with a medical device called Simeox4, which applies gentle intermittent negative pressure during exhalation to help move air out of the lungs more easily. The research aims to explore whether this device can reduce residual volume, the amount of air left in the lungs after a full exhalation. Participants undergo lung function tests before and immediately after a 20-minute Simeox4 session, which consists of four sets of ten slow, controlled breathing cycles while seated. During exhalation, the device applies high-frequency negative pressure adjusted to the maximum intensity tolerated by the patient. Lung function is measured using spirometry and nitrogen wash-out techniques. No control group is involved as all enrolled patients receive the Simeox4 treatment. Throughout the session, vital signs such as respiratory rate, heart rate, and oxygen saturation are monitored. Researchers track any side effects and assess how well participants tolerate the treatment. The main outcome is the change in residual volume measured within 30 minutes after treatment. Other lung volumes, breathlessness scores, and safety information are also recorded. This pilot study of 23 patients serves as a foundation for future larger trials with longer follow-up periods.
CONDITIONS
Effect of Simeox® on Residual Volume in COPD Patients With Pulmonary Hyperinflation
A
Andrea Di Matteo, dr
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Azienda Socio Sanitaria Territoriale di Lodi
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single visit lasting approximately 1 hour
Participants undergo baseline lung function tests, then receive a single 20-minute Simeox4 device session applying intermittent negative pressure during exhalation. Lung function tests are repeated immediately after treatment to assess changes.
1 visit (in-person)
Duration - Up to 30 minutes after treatment session
Vital signs like respiratory rate, heart rate, and oxygen saturation are monitored during and up to 30 minutes after treatment. Adverse events and treatment tolerability are recorded.
Continuous monitoring during treatment visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Denis E O'Donnell, Pierantonio Laveneziana
https://pubmed.ncbi.nlm.nih.gov/17729066/Jorine E Hartman, Nick H T Ten Hacken, Karin Klooster...
https://pubmed.ncbi.nlm.nih.gov/22441742/Henry E Fessler, Steven M Scharf, Solbert Permutt
https://pubmed.ncbi.nlm.nih.gov/11779727/J Wanger, J L Clausen, A Coates...
https://pubmed.ncbi.nlm.nih.gov/16135736/Christopher B Cooper
https://pubmed.ncbi.nlm.nih.gov/16996896/Luis Puente-Maestu, William W Stringer
https://pubmed.ncbi.nlm.nih.gov/18044095/Nicholas S Hopkinson, Tudor P Toma, David M Hansell...
https://pubmed.ncbi.nlm.nih.gov/15579725/Francisco Garcia-Rio, Vanesa Lores, Olga Mediano...
https://pubmed.ncbi.nlm.nih.gov/19542481/Azienda Socio Sanitaria Territoriale di Lodi
Lead Sponsor